Select Page

Growing research and development activities in the field of genomics complemented by the advent of technologically robust genetic platforms such as NGS (Next Generation Sequencing) continue to influence the global monoclonal antibody market. This factor coupled with cost-efficient characteristics of the next generation sequencing and other technologies has proven vital in their incorporation in analyzing and performing deep research to develop monoclonal antibodies (mABS). These widely accepted biologics are expected to present huge opportunities to manufacturers in the pharmaceutical domain to develop novel drugs for chronic disorders.

In addition to biologics of monoclonal antibody, increasing awareness among physicians and patients alike with respect to potential uses of monoclonal antibody therapies are expected to pave new avenues of growth for the monoclonal antibody market worldwide. Moreover, approval of use of monoclonal antibodies in drugs to treat various indications is expected to create a surge in demand for monoclonal antibodies in turn triggering their market’s growth. For example, drugs such as Herceptin, Avastin, Rituxan, and Remicade that have FDA approval for use across an array of conditions including but not limited to cancer, arthritis and ulcerative colitis have not only generated higher revenues but also created a massive patient pool. This aspect continues to fuel the use of monoclonal antibody in drug development for treating various chronic disorders, consequently supporting the growth of the global monoclonal antibody market.

Get Free Sample PDF (including full TOC, Tables and Figures) of Monoclonal Antibody Market @ https://www.crediblemarkets.com/sample-request/monoclonal-antibody-market-486426 

Humanized monoclonal antibody likely to maintain its strong status quo in the market

The demand for humanized monoclonal antibody is expected to witness moderate growth in the years to follow. However, the market valuation for humanized monoclonal antibody is estimated to account for a major share in the global monoclonal antibody market. This is mainly attributed toward use of humanized monoclonal antibodies in treating various disorders such as inflammatory diseases, autoimmune diseases and mainly cancer. The growth in the market scenario of humanized monoclonal antibody is also complemented by the application of advanced technologies such as transgenic mice and yeast display for their development. 

North America to dominate the monoclonal antibody market followed by European and Asian Countries

The monoclonal antibody market in North America, particularly in the United States is estimated to account for a major share in the global marketplace. Increasing cancer incidences in the country, coupled with favourable government support to healthcare facilities and favourable funding are few of the factors influencing the use of novel therapies in treating chronic conditions and use of mABS is no exception. On the other hand, the monoclonal antibody demand is expected to increase across various Asian countries, mainly due to rising lifestyle diseases coupled with increasing population. Emerging countries such as China and India are likely to contribute to the growing demand for use of monoclonal antibody in drug development to fight various lifestyle diseases. 

Global Monoclonal Antibody Market Players are: Roche Pharmaceuticals, Johnson & Johnson, Merck, Novartis, AbbVie, Amgen, Shanghai Lansheng States Kin Pharmaceutical, Beijing Biotech Pharmaceutical, Shanghai CP Guojian Pharmaceutical, Shanghai Zhangjiang Biotech, Shanghai CP GuoJian Biotech Academy, Shanghai Guosheng Pharmaceutical, Chengdu Huasun Group, Shanghai Medipharm Biotech, Zhejiang Hisun Pharmaceutical, Yunnan Walvax Biotechnology, Shanghai Fosun Pharmaceutical, Beijing SL Pharmaceutical, Shenzhen Main Luck Pharmaceuticals, Huahai Pharmaceutical, Livzon Pharmaceutical Group, Hualan Biological Engineering

Alternative treatments to emboss a negative impact on the monoclonal antibody market 

Natural remedies and alternative treatments are gaining steam across the globe on the back of slow yet effective and promising results, convenience in use and dosage and relatively cheaper pricing. On-going advances in the treatments across various domains such as Ayurveda and Homeopathy and acceptance of yoga sujok and acupuncture therapies are gaining popularity. The revenue generated by these therapies is also rising, yet at a moderate pace, however impacting the use of monoclonal antibody in drugs, subsequently impacting their sales. For instance, in 2017 the retail sales of herbal and homeopathy medicines in the US were around USD 7 billion. Likewise, traditional market valuation increased by USD 161 billion to touch USD 360 billion in 2017 from 2015 in the country. Less expensive nature of the alternate remedies is expected to fuel their demand exerting a negative influence on the global monoclonal antibody market. 

Direct Purchase Report @ https://www.crediblemarkets.com/reports/purchase/monoclonal-antibody-market-486426?utf8=%E2%9C%93&license_type=single_user 

COVID-19 can be neutralized using monoclonal antibody, either in combination or by itself

The COVID-19 pandemic, albeit its negative impact on various markets, is expected to present potential avenues to manufacturers of monoclonal antibody. This is directly related to the efficiency of monoclonal antibody in fighting against coronavirus as monoclonal antibody, either in combination with or by itself has the potential to treat and/or prevent COVID-19. Scientists predict that the use of monoclonal antibody in making drugs for COVID-19 can also be extended to future emerging diseases caused in humans by viruses from Sarbecovirus subgenus. Against this backdrop, pharmaceutical companies have started development and testing of novel drugs made from monoclonal antibody to treat COVID-19. For instance, Astrazeneca is planning to start a phase 1 trial of monoclonal antibody therapy to treat COVID-19 in the second quarter of 2020. The pharmaceutical giant stresses on the fact that the combination of two monoclonal antibodies could be a single effective preventive therapy against the virus by performing a neutralizing effect. 

KEY QUESTIONS ANSWERED IN THE REPORT

  • What is the market size and growth rate of the global and regional markets by various segments?
  • What is the market size and growth rate of the market for selective countries?
  • Which region or sub-segment is expected to drive the market during the forecast period?
  • What factors are anticipated to impact demand and supply trends in the market during the forecast period? 
  • What factors are likely to drive market revenue growth during the forecast period?
  • What are the key technology and other trends shaping the market?
  • What are the key opportunities in the market?
  • What are some of the strategies implemented by key companies operating in the market?
  • What is the COVID-19 impact on the market?

 

For More Information About this Report Visit @ https://www.crediblemarkets.com/market-analysis/monoclonal-antibody-market-486426 

ABOUT CREDIBLE MARKETS

Credible Markets is a new-age market research company with a firm grip on the pulse of global markets. Our research reports leverage predictive analytical models to study the performance of critical markets, helping businesses make strategic, informed decisions.

Contact Us

Phone: +1(929)-450-2887 

Emailsales@crediblemarkets.com 

Websitehttps://www.crediblemarkets.com